RxDoctor Payments DataLook up a doctor →

Nirav Mehta, MD

Interventional Cardiology · Surprise, AZNPI 1801865415

Payments from drug & device makers

$61,705in general payments, 2019–2025

Across 898 payments — averaging $68.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$15K
  • Philips North America LLC$13K
  • Medtronic$10K
  • Boston Scientific$4K
  • Abiomed$3K
  • Cardiovascular Systems Inc.$2K
  • plus $14K from 44 others

What the payments were for

  • Consulting fees$7,80013%
  • Speaking & faculty fees$6,30010%
  • Grants$1,6673%
  • Travel & lodging$10,76817%
  • Food & beverage$34,63156%
  • Education$2580%
  • Other$2820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,705 in reported general payments places this provider in the 80th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$586,679
Medicare patients
1,030
Services billed
4,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$262,807
EntrestoSacubitril/Valsartan62$57,560
XareltoRivaroxaban36$57,288
Repatha SureclickEvolocumab51$49,341
BrilintaTicagrelor13$17,339
Praluent PenAlirocumab11$8,948
Flecainide Acetate110$6,772
NexletolBempedoic Acid11$5,351
Metoprolol Succinate333$4,388
ClopidogrelClopidogrel Bisulfate305$3,283
Nebivolol Hcl55$3,102
Rosuvastatin Calcium153$2,042
Atorvastatin Calcium208$1,925
Amiodarone Hcl44$1,750
SotalolSotalol Hcl107$1,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$416$262,807198 claims
NovartisEntresto$849$57,56062 claims
Johnson & JohnsonXarelto$82$57,28836 claims
AstraZenecaBrilinta$323$17,33913 claims
Esperion Therapeutics, Inc.Nexletol$12$5,35111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →